Biofrontera (BFRI) Share-based Compensation (2021 - 2025)
Biofrontera's (BFRI) quarterly Share-based Compensation came in at $289000.0 in Q4 2025, down 70.87% year-on-year from $992000.0 in Q4 2024, and up 189.0% quarter-over-quarter from $100000.0 in Q3 2025.
Biofrontera (BFRI) Share-based Compensation (2021 - 2025) Analysis & Trends
Biofrontera's Share-based Compensation history runs 5 years deep, the most recent figure standing at $289000.0 for Q4 2025.
- On a quarterly basis, Share-based Compensation fell 70.87% year-over-year to $289000.0 in Q4 2025; TTM through Dec 2025 was $1.5 million, a 2.57% decrease from a year earlier, with the FY2025 full-year figure at $951000.0, down 6.67% from the prior year.
- Share-based Compensation grew to $289000.0 in Q4 2025 per BFRI's latest filing, from $100000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.7 million in Q2 2022 and bottomed at -$17000.0 in Q4 2023.
- The 5-year median for Share-based Compensation is $228000.0 (2024), against an average of $463058.8.
- Across the five-year window, Share-based Compensation sank 104.44% in 2023 and soared 5935.29% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $129000.0 in 2021, then surged by 196.9% to $383000.0 in 2022, then slumped by 104.44% to -$17000.0 in 2023, then surged by 5935.29% to $992000.0 in 2024, then slumped by 70.87% to $289000.0 in 2025.
- Per Business Quant, the three latest BFRI Share-based Compensation figures stand at $289000.0 (Q4 2025), $100000.0 (Q3 2025), and $700000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn | 289,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 289,000.00 |
| Dec 31, 2025 | 289,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 900,000.00 |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 992,000.00 |
| Dec 31, 2024 | 992,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | -17,000.00 |
| Dec 31, 2023 | -17,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |